GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » EV-to-EBITDA

LBPWQ (4d pharma) EV-to-EBITDA : 0.00 (As of Oct. 31, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 4d pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, 4d pharma's enterprise value is $0.00 Mil. 4d pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 was $-75.58 Mil. Therefore, 4d pharma's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for 4d pharma's EV-to-EBITDA or its related term are showing as below:

LBPWQ's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.55
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-10-31), 4d pharma's stock price is $0.0001. 4d pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $0.000. Therefore, 4d pharma's PE Ratio (TTM) for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


4d pharma EV-to-EBITDA Historical Data

The historical data trend for 4d pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma EV-to-EBITDA Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Get a 7-Day Free Trial -7.38 -1.74 -2.18 -5.59 -1.63

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.18 - -5.59 - -1.63

Competitive Comparison of 4d pharma's EV-to-EBITDA

For the Biotechnology subindustry, 4d pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4d pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where 4d pharma's EV-to-EBITDA falls into.



4d pharma EV-to-EBITDA Calculation

4d pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-75.578
=0.00

4d pharma's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4d pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 was $-75.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4d pharma  (OTCPK:LBPWQ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

4d pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/0.000
=N/A

4d pharma's share price for today is $0.0001.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4d pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


4d pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of 4d pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma Business Description

Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma Headlines

From GuruFocus

4D Pharma to Present at Upcoming Investor Conferences in March

By Business Wire Business Wire 03-03-2021

4D pharma appoints John Doyle as Chief Financial Officer

By Business Wire Business Wire 01-03-2022

4D pharma to Present at the H.C. Wainwright BioConnect Conference

By Business Wire Business Wire 01-05-2022